Skip to main content

GlaxoSmithKline Plc Value Stock - Dividend - Research Selection

GlaxoSmithKline Plc

ISIN: GB0009252882, WKN: 940561

Market price date: 24.05.2021
Market price: 13,55 GBP

GlaxoSmithKline Plc Fundamental data and company key figures of the share

Annual reports in GBP
Key figures 08-02-2021
Cash flow
Net operating cash flow 7.647.000.000
Capital Expenditures -
Free cash flow 6.421.000.192
Balance sheet
Total Equity 20.808.000.000
Liabilities & Shareholders equity 80.431.000.000
Income statement
Net income 5.749.000.000
Eps (diluted) 1,140
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on: 24-05-2021

Key figures 24-05-2021
Cash flow
P/C 8,91
P/FC 10,61
Balance sheet
Income statement
Div. Yield5,92%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization89.670.565.888,00 USD
IndicesFTSE 100
Raw Data SourceIFRS in Millionen GBP
Stock Split2000-12-27,775.0000/1704.0000; 2000-12-26,775.0000/1704.0000; 1996-08-12,1030.0000/1013.0000; 1991-10-28,2.0000/1.0000; 1989-11-24,2.0000/1.0000

Description of the company

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK's principal pharmaceutical products include medicines in therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company operates in three primary areas of business: Pharmaceuticals, Vaccines and Consumer Healthcare. On January 30, 2013, GSK acquired additional 29.3% interest in GlaxoSmithKline Consumer Healthcare Ltd. In May 2013, GlaxoSmithKline PLC acquired Okairos AG.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,